Accession Number: | 0000921895-22-001898 |
Date: | 2022-06-01 |
Issuer: | CULLINAN ONCOLOGY, INC. (CGEM) |
Original Submission Date: |
BVF PARTNERS L P/IL
44 MONTGOMERY ST.
40TH FL
SAN FRANCISCO, CA 94104
BIOTECHNOLOGY VALUE FUND L P
44 MONTGOMERY ST.
40TH FL
SAN FRANCISCO, CA 94104
BVF I GP LLC
44 MONTGOMERY ST., 40TH FLOOR
SAN FRANCISCO, CA 94104
BIOTECHNOLOGY VALUE FUND II LP
44 MONTGOMERY ST.
40TH FL
SAN FRANCISCO, CA 94104
BVF II GP LLC
44 MONTGOMERY ST., 40TH FLOOR
SAN FRANCISCO, CA 94104
BIOTECHNOLOGY VALUE TRADING FUND OS LP
P.O. BOX 309 UGLAND HOUSE
GRAND CAYMAN, E9 KY1-1104
BVF PARTNERS OS LTD.
P.O. BOX 309 UGLAND HOUSE
GRAND CAYMAN, E9 KY1-1104
BVF GP HOLDINGS LLC
44 MONTGOMERY ST., 40TH FLOOR
SAN FRANCISCO, CA 94104
BVF INC/IL
44 MONTGOMERY ST.
40TH FL
SAN FRANCISCO, CA 94104
LAMPERT MARK N
44 MONTGOMERY ST.
40TH FL
SAN FRANCISCO, CA 94104
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2022-06-01 | P | 405,641 | a | $11.00 | 4,058,854 f2 | direct | ||
COMMON STOCK | 2022-06-01 | P | 301,009 | a | $11.00 | 2,992,808 f3 | direct | ||
COMMON STOCK | 2022-06-01 | P | 44,746 | a | $11.00 | 364,161 f4 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | this form 4 is filed jointly by biotechnology value fund, l.p. ("bvf"), biotechnology value fund ii, l.p. ("bvf2"), biotechnology value trading fund os lp ("trading fund os"), bvf partners os ltd. ("partners os"), bvf i gp llc ("bvf gp"), bvf ii gp llc ("bvf2 gp"), bvf gp holdings llc ("bvf gph"), bvf partners l.p. ("partners"), bvf inc. and mark n. lampert (collectively, the "reporting persons"). each of the reporting persons is a member of a section 13(d) group. each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. |
f2 | securities owned directly by bvf. as the general partner of bvf, bvf gp may be deemed to beneficially own the securities owned directly by bvf. as the sole member of bvf gp, bvf gph may be deemed to beneficially own securities owned directly by bvf. as the investment manager of bvf, partners may be deemed to beneficially own the securities owned directly by bvf. as the investment adviser and general partner of partners, bvf inc. may be deemed to beneficially own the securities owned directly by bvf. as a director and officer of bvf inc., mr. lampert may be deemed to beneficially own the securities owned directly by bvf. |
f3 | securities owned directly by bvf2. as the general partner of bvf2, bvf2 gp may be deemed to beneficially own the securities owned directly by bvf2. as the sole member of bvf2 gp, bvf gph may be deemed to beneficially own securities owned directly by bvf2. as the investment manager of bvf2, partners may be deemed to beneficially own the securities owned directly by bvf2. as the investment adviser and general partner of partners, bvf inc. may be deemed to beneficially own the securities owned directly by bvf2. as a director and officer of bvf inc., mr. lampert may be deemed to beneficially own the securities owned directly by bvf2. |
f4 | securities owned directly by trading fund os. as the general partner of trading fund os, partners os may be deemed to beneficially own the securities owned directly by trading fund os. as the investment manager of trading fund os and the sole member of partners os, partners may be deemed to beneficially own the securities owned directly by trading fund os. as the investment adviser and general partner of partners, bvf inc. may be deemed to beneficially own the securities owned directly by trading fund os. as a director and officer of bvf inc., mr. lampert may be deemed to beneficially own the securities owned directly by trading fund os. |